QTRX vs. FLDM, LAB, CTKB, PACB, EYPT, NAUT, HBIO, SEER, AKYA, and BNGO
Should you be buying Quanterix stock or one of its competitors? The main competitors of Quanterix include Fluidigm (FLDM), Standard BioTools (LAB), Cytek Biosciences (CTKB), Pacific Biosciences of California (PACB), EyePoint Pharmaceuticals (EYPT), Nautilus Biotechnology (NAUT), Harvard Bioscience (HBIO), Seer (SEER), Akoya Biosciences (AKYA), and Bionano Genomics (BNGO).
Fluidigm (NASDAQ:FLDM) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, community ranking, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.
Fluidigm received 249 more outperform votes than Quanterix when rated by MarketBeat users. Likewise, 65.48% of users gave Fluidigm an outperform vote while only 61.66% of users gave Quanterix an outperform vote.
Quanterix has a net margin of -28.82% compared to Quanterix's net margin of -45.36%. Fluidigm's return on equity of -10.39% beat Quanterix's return on equity.
Quanterix has lower revenue, but higher earnings than Fluidigm. Quanterix is trading at a lower price-to-earnings ratio than Fluidigm, indicating that it is currently the more affordable of the two stocks.
76.6% of Fluidigm shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 2.9% of Fluidigm shares are owned by company insiders. Comparatively, 6.9% of Quanterix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Quanterix had 6 more articles in the media than Fluidigm. MarketBeat recorded 6 mentions for Quanterix and 0 mentions for Fluidigm. Fluidigm's average media sentiment score of 1.14 beat Quanterix's score of 0.28 indicating that Quanterix is being referred to more favorably in the news media.
Quanterix has a consensus target price of $30.60, indicating a potential upside of 80.00%.
Fluidigm has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.
Summary
Quanterix beats Fluidigm on 11 of the 16 factors compared between the two stocks.
Get Quanterix News Delivered to You Automatically
Sign up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quanterix Competitors List
Related Companies and Tools
